# Efficacy and Safety of Grass Pollen Sublingual Immunotherapy

> **NCT00567346** · PHASE2,PHASE3 · COMPLETED · sponsor: **Artu Biologicals** · enrollment: 605 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **DRUG:** Oralgen
- **DRUG:** grass pollen extract

## Key facts

- **NCT ID:** NCT00567346
- **Lead sponsor:** Artu Biologicals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-10
- **Final completion:** 2008-03
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2010-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567346, "Efficacy and Safety of Grass Pollen Sublingual Immunotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00567346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*